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Abstract This article deals with some of the recent 
evidence bearing on the issues of the liability of 
benzodiazepines to lead to abuse, dependence, and 
adverse behavioral effects. Reviews of epidemiological, 
clinical and experimental literature indicated that the 
previous conclusion about abuse of these drugs still 
holds: the vast majority of the use of benzodiazepines 
is appropriate. Problems of nonmedical use arise 
nearly exclusively among people who abuse other drugs. 
Nevertheless, there are reasons for concern about 
patients who take benzodiazepines regularly for long 
periods of time. These drugs can produce physiologi- 
cal dependence when taken chronicaly, and although 
this does not appear to result in dose escalation or 
other evidence of "psychological dependence," physio- 
logical dependence can result in patient discomfort if 
drug use is abruptly discontiniued. Also, physicians are 
currently prescribing shorter-acting benzodiazepines in 
preference to longer-acting benzodiazepines. The short- 
er-acting drugs can produce a more intense withdrawal 
syndrome following chronic administration. Further- 
more, rates of use of benzodiazepines increase with age, 
and elderly patients are more likely than younger ones 
to take the drug chronically. The clearest adverse effect 
of benzodiazepines is impairment of memory. This, too, 
may be particular concern in older patients whose recall 
in the absence of drug is typically impaired relative to 
younger individuals, and who are more compromised 
following drug administration. 
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Introduction 
Benzodiazepines have long been a subject of lively 
scientific and public interest, and this interest remains 
intense. Our 1987 review of the liability of benzodi- 
azepines for abuse, dependence, and adverse behavioral 
effects (Woods et al. 1987, 1988) covered the relevant 
literature of the previous 25 years, since the drugs were 
introduced. This substantial literature had remarkably 
doubled 5 years later, when we reviewed it again (Woods 
et al. 1992). In brief, both reviews concluded that the 
vast majority of use of these drugs is appropriate, with 
no important risk of abuse among the general popu- 
lation or typical patients. 
In the present article we wish to draw" attention to 
some key issues of current interest. In preparing this 
article, we have considered some of the most recent 
information bearing on these issues; the new data 
sharpen the picture, but do not alter our basic con- 
clusions. We hope here to provide a perspective on what 
has been learned and, equally important, what remains 
to be learned about the ways in which these drugs are 
now used and the consequences of this use. 
In view of the extensive use of benzodiazepines over 
the past 30 years, epidemiology should logically serve 
as our primary guide in identifying issues deserving 
scrutiny. In fact, the literature on the epidemiology of 
benzodiazepine use is vast, and is distinguished by a 
very substantial agreement among diverse sources of 
information about how these drugs are used. One of 
the most consistent findings continues to be that, while 
most patients receiving benzodiazepine prescriptions 
use the drugs only for relatively brief periods, a size- 
able minority has used benzodiazepines for long 
periods of time. In the United States, the annual preva- 
lence of use of benzodiazepine anxiolytics declined 
from 11.1% to 8.3% between 1979 and 1990. However, 
one in four users in 1990 had used these drugs regu- 
larly for a year or longer; somewhat fewer users of 
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benzodiazepine hypnotics (14%) reported long-term 
use (Balter 1991). Rates of use increase with age, so 
that elderly patients account for a disproportionately 
large percentage of benzodiazepine prescriptions; in the 
United States in 1991, while those 65 or older repre- 
sented about 13 % of the population (Golenpaul 1991), 
they received 27% of all prescriptions for benzodi- 
azepine tranquilizers and 38 % of prescriptions :for ben- 
zodiazepine hypnotics (IMS America Ltd. National 
Disease and Therapeutic Index 1991). Elderly patients 
are also more likely than younger patients to continue 
use for long periods. Although characteristics of ben- 
zodiazepine users have not changed appreciably in 
recent years, there has been a dramatic shift in the 
specific agents used. In many countries, including the 
United States, use of the longer-acting compounds has 
been substantially supplanted by increased use of the 
shorter-acting agents; also, while use of benzodiazepine 
anxiolytics has declined, use of benzodiazepine hyp- 
notics has remained stable or increased (Woods et al. 
1992). These characteristics of the actual use of 
benzodiazepines help to focus the following discussion 
of our findings relative to current benzodiazepine 
issues. 
Abuse versus therapeutic use 
Some authors have expressed the view that the great 
prevalence of use of benzodiazepines must reflect over- 
prescription and relate to the drugs' liability for abuse 
and dependence; others have attributed it to the preva- 
lence of the disorders for which benzodiazepines are 
prescribed. Our first review (Woods et al. 1987, 1988) 
suggested that these divergent views of benzodiazepine 
use (which we termed the "abuse model" and the "ther- 
apeutic use model") arose from studies of two distinct 
populations. Epidemiologic studies had found that 
non-medical use of benzodiazepines is rare in the 
general population, but relatively frequent among pop- 
ulations of drug abusers; these findings paralleled 
experimental research, which found little or no prefer- 
ence for benzodiazepines among normal or anxious 
subjects, but some limited reinforcing effects of these 
drugs among subjects with histories of drug abuse. 
Other survey data had demonstrated that most actual 
use of benzodiazepines is appropriate, in that users'in 
the community do have the disorders for which ben- 
zodiazepines are deemed effective. Although clinical 
research had found that prolonged use of therapeutic 
doses can lead to physiological dependence, this depen- 
dence is not usually accompanied by a tendency to 
escalate doses or other behaviors characteristic of 
"psychological dependence" or "addiction." We con- 
cluded that the widespread use of benzodiazepines is 
explained better by the "therapeutic use model" than 
by the "abuse model". 
Recent findings 
Recent epidemiologic studies have lent support to ear- 
lier findings, from national household surveys in the 
United States (Mellinger et al. 1978, 1984a), that actu- 
al use of benzodiazepines is generally appropriate. 
Community surveys in the United States (Swartz et al. 
1991) and Western Europe (Fichter et al. 1989; Pakesch 
et al. 1989; Vazquez-Barquero et al. 1989) have found 
significant positive correlations between benzodi- 
azepine use and psychiatric disturbance as measured 
using standard rating instruments. Among patients of 
general practices, those who had receipted prescriptions 
for benzodiazepines scored significantly higher on such 
ratings than matched controls who had not received 
such prescriptions (Salinsky and Dore 1987; Gen6e- 
Badia et al. 1988) Other studies of general medical 
patients in the United States (Haskell et al. 1986; Ried 
et al. 1990) and Western Europe (Magni et al. 1986; 
Bellantuono et al. 1989; Antonijoan et al. 1990) also 
showed that benzodiazepine users were distinguished 
by significant psychiatric morbidity; some of these 
(Magni et aI. 1986; Antonijoan et al. 1990; Ried et al. 
1990) specifically studied elderly patient populations. 
Other recent research has documented continuing 
declines in non-medical use of benzodiazepines in the 
general population. Periodic household surveys by the 
National Institute on Drug Abuse (NIDA) have shown 
that, between 1985 and 1992, annual rates of non-med- 
ical use of tranquilizers decreased by more than half 
among adolescents (12-17 years), young adults 
(18 25), and adults (26 and older; National Household 
Survey on Drug Abuse: Main Findings 1991). In 1992, 
between 1% and 3% of a national sample reported non- 
medical use within the previous year, and 0.6% or less 
within the previous month (National Household 
Survey on Drug Abuse: Main Findings 1991; National 
Household Survey on Drug Abuse: Population 
Estimates 1992). Annual NIDA surveys of high school 
seniors and college students found similar declines in 
non-medical use of tranquilizers over this period 
(Johnston et al. 1993a,b). 
Risk factors for abuse 
These recent data lend further support to the view that 
most use of benzodiazepines is appropriate, and that 
these drugs have little liability for abuse in most pop- 
ulations. Nevertheless, as Cooper et al. remarked in this 
context, "it would be naive to fail to recognize that a 
minority of those seeking treatment are or will become 
drug abusers...." (Johnston et al. 1993a). Recent 
research provides some interesting suggestions about 
possible risk factors for abuse of benzodiazepines in 
typical patient populations. 
For example, although physiological dependence in 
itself is not usually accompanied by a tendency to 
increase dosage or to recreational use, at least one study 
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has suggested that abrupt withdrawal from benzodi- 
azepine treatment might increase the tendency to self- 
administer the drugs (Cappell et al. 1987). If this finding 
were replicated, it would raise the possibility that efforts 
to discontinue benzodiazepine treatment abruptly 
might lead to inappropriate continued use in 
dependent patients. The same study, however, also sup- 
ported current recommendations to discontinue ben- 
zodiazepine treatment by gradual tapering, since 
patients discontinued in this way were significantly less 
likely to self-administer the drugs. 
Perhaps the most intriguing finding of recent 
experiments in human self-administration of benzodi- 
azepines was that moderate drinkers, i.e. subjects who 
consumed an average of 11 alcholic drinks weekly, con- 
sistently chose to take diazepam rather than placebo 
after they had learned to differentiate the capsules. This 
was in marked contrast to earlier studies by the same 
investigators, in which most normal or anxious sub- 
jects showed no preference for diazepam (De Wit et al. 
1989). Since moderate drinkers might represent a 
"bridge" between the normal population and sedative 
abusers, further studies of these subjects could help to 
elucidate the characteristics that make some people and 
not others susceptible to benzodiazepine abuse. 
Physiological dependence 
patients who had used the drugs for relatively long peri- 
ods, and it was assumed that the risk increased with 
duration of use; studies in animals supported that view 
(Woods et al. 1987). However, more recent human stud- 
ies have demonstrated withdrawal after relatively brief 
periods of use, e.g. 2 weeks (Orsini et al. 1990); and 
studies comparing discontinuation after different peri- 
ods of treatment have found no difference in the inci- 
dence of withdrawal (Orsini et al. 1990). Other factors 
that have been considered as possible determinants of 
the development of physiological dependence have 
included drug half-life, magnitude of dose, patients' 
prior drug use, age, and personality traits; while some 
of these factors have influenced the development of 
dependence in animals (Woods et al. 1992), none has 
yet been shown to be clearly related to the risk of depen- 
dence in patients. 
In 1990, 23 % of US adults who used benzodiazepine 
hypnotics had used the drugs nightly for at least 4 
months (Balter 1991). Since hypnotic prescriptions 
have increasingly called for the short-acting triazolam, 
a considerable proportion of chronic hypnotic use now 
consists of repeated intermittent, rather than continu- 
ous, exposure to the agonist. Apart from studies of 
rebound insomnia, which is a withdrawal phenomenon, 
there has been no systematic investigation of the lia- 
bility of this type of therapeutic regimen to produce 
physiological dependence. 
Physiological dependence is a state induced by drug 
treatment that results in a time-limited withdrawal 
reaction when treatment is discontinued (or when a 
benzodiazepine antagonist, such as flumazenil, is 
administered). One of the issues most frequently dis- 
cussed in recent literature on benzodiazepines has been 
the risk that physiological dependence can develop even 
when the drugs are administered only at doses within 
the recommended therapeutic range. Although this risk 
was suspected by about 1980, and has subsequently 
been confirmed and to some extent characterized in 
numerous clinical studies, our understanding of many 
basic aspects of the phenomenon and of its significance 
has not advanced appreciably. 
Risk factors 
The studies that established the potential of benzodi- 
azepines to produce physiological dependence at ther- 
apeutic doses also found that not all patients using 
these drugs became dependent, i.e. some did not show 
signs of withdrawal when the drugs were discontinued. 
More recent studies have supported this finding, 
although they have not clarified what proportion of 
users do become dependent nor the determinants of 
dependence. 
The early studies of therapeutic dose dependence 
generally examined the effects of discontinuation in 
Effects 
Some authors have argued that the risk of physiologi- 
cal dependence is so serious that use of benzodiazepines 
should be much more strictly limited or curtailed. 
However, despite the large numbers of long-term users, 
many of whom may be physiologically dependent on 
these drugs, we have yet to see persuasive evidence of 
harm arising from this dependence per se - apart, that 
is, from the phenomena of withdrawal upon discon- 
tinuation. Clinical studies have continued to show that 
the discomfort of withdrawal can be minimized by 
gradual tapering of dosage (Busto et al. 1986; 
Cantopher et al. 1990; Schweizer et al. 1990). 
Although it has not been established whether depen- 
dence is more or less likely to develop with short 
versus long half-life benzodiazepines, recent studies 
have shown that abrupt withdrawal from the short-act- 
ing drugs develops more rapidly and may be more 
intense than withdrawal from benzodiazepines with 
longer durations of action (Rickels et al. 1988; 
Schweizer et aI. 1990; Noyes et al. 1991). It has also 
been found that effective discontinuation of short-act- 
ing benzodiazepines, to minimize the risk of rebound 
symptoms and other effects of withdrawal, requires a 
particularly gradual and prolonged tapering regimen 
(Mellman and Uhde 1986; Fyer et al. 1987; Pecknold 
et al. 1988; Noyes et al. 1991) and that, at least in the 
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short term, patients discontinued from these drugs are 
more likely to resume use than are patients discontin- 
ued from long-acting agents (Rickels et al. 1990). 
In the longer term following discontinuation, the 
likelihood of continued abstinence does not appear to 
depend on the type of benzodiazepine used, dosage 
before discontinuation, nor the intensity of withdraw- 
al phenomena; it is unclear whether the duration of 
treatment before discontinuation affects subsequent 
abstinence (Ashton 1987; Golombok et al. 1987; 
Rickels et al. 1991). Some studies have found that 
younger patients are more likely than older patients to 
remain abstinent after discontinuing benzodiazepine 
treatment. (Ashton 1987; Rickels et al. 1991). This 
would not appear to be related to the relative severity 
of withdrawal, however, since withdrawal may actually 
be less intense among older patients (Schweizer et al. 
1989). Another recent finding bearing on discontinua- 
tion of benzodiazepines is that, unlike detoxified and 
abstinent alcoholics, patients discontinued from ben- 
zodiazepines express little or no "craving" to resume 
use of these drugs (Lucki et al. 1991). 
Prevention 
Despite concerns about the risk of physiological 
dependence on benzodiazepines, there has been little 
consideration of ways in which dependence might be 
prevented from the onset of treatment. Clinical author- 
ities have long recommended that use shotfld be 
interrupted by occasional "drug holidays," which 
would permit reassessment of the need to continue 
treatment and might also reduce the risk of dependence 
development. However, the effect of drug-free intervals 
on the development of dependence has not been stud- 
ied under controlled conditions. If it can be shown that 
such intervals actually can prevent or delay the devel- 
opment of dependence, more systematic research will 
be needed to specify how best to schedule them. 
Another possible approach to prevention has been 
suggested by studies of chronic benzodiazepine treat- 
ment in animals; periodic injections of a benzodi- 
azepine antagonist significantly reduced the intensity 
of the subsequent withdrawal syndrome (Gallager et al. 
1986). The suggestion that it might be possible in this 
way to "reset the clock" for the initiation of depen- 
dence needs to be pursued through studies of a vari- 
ety of benzodiazepines in both animals and humans. 
Adverse behavioral effects 
Laboratory studies of the effects of benzodiazepines on 
various types of psychomotor performance continue to 
appear in large numbers, and remain disappointing 
with respect to the consistency of results. The most 
consistent finding is that single doses of all benzodi- 
azepines tested can be shown to impair some types of 
performance, though no particular type of performance 
is affected reliably across studies. While earlier studies 
indicated that these decrements tended to diminish 
when doses were repeated, as would be typical of ther- 
apeutic use, some recent experiments suggest that some 
types of impairment may be sustained with chronic 
dosing; however, results of such studies again are incon- 
sistent, and these findings remain inconclusive. Among 
the experimental behaviors affected by benzodiazepines 
are performances in simulated or real automobile 
driving. However, whether such drug effects actually 
contribute to driving accidents can be established only 
by case-controlled epidemiologic studies of drivers 
involved in accidents; the available evidence is not ade- 
quate to the question (Ray 1992; Woods et al. 1992). 
The greatest recent advance in our understanding of 
the psychomotor effects of benzodiazepines comes from 
increasingly sophisticated research on human recall. It 
can now be shown reliably that acute doses of these 
drugs can markedly impair recall, and especially 
delayed recall (recall of stimuli presented some time 
earlier, as opposed to immediate recall). With regard 
to the usual therapeutic condition of repeated dosing, 
one well-designed experiment (Lucki and Rickels 1988) 
suggests that chronic users experience impairment of 
delayed recall during short periods of time following 
each dose. However, further systematic study is need- 
ed to establish whether and to what extent tolerance 
may develop to any or all of the drugs' amnestic effects. 
Further research is also required to pursue important 
recent suggestions that benzodiazepines may vary sub- 
stantially in their effects on recall (Woods et aI. 1992). 
Elderly patients 
It has been suggested for m a w  years by many authors 
that elderly patients may be especially sensitive to the 
effects of benzodiazepines. Certainly this suggestion is 
well grounded in the pharmacokinetics of aging, and 
has been reinforced by the epidemiologic demonstra- 
tion of a greater incidence of adverse CNS reactions 
in older patients taking these drugs (Greenblatt et al. 
1989). However, our review of the literature (Woods 
et al. 1992) as well as other recent reviews (Gurwitz 
and Avorn 1991; Ray 1992) concludes that the rela- 
tionship between age and relative susceptibility to 
adverse effects from benzodiazepines and other drugs 
is more complex than previously thought, and remains 
controversial. 
For example, a number of recent epidemiological 
studies have examined the association between use of 
benzodiazepines and the risk of falls and/or hip frac- 
tures in elderly populations. Some of these studies 
(Sobel and McCart 1983; Hale et al. 1985; Oster et al. 
1987, 1990; Ray et al. 1987, 1989; Cummings et al. 
1991; Myers et al. 1991) but not others (Wells et al. 
1985; Sorock and Shimkin 1988; Grisso et al. 1991; 
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Trewin et al. 1992) have found a significant positive 
association. However, this research has been helpful in 
identifying other factors that may increase this risk as 
much as or more than the benzodiazepines do, 
including the use of other psychoactive and non-psy- 
choactive drugs as well as medical disorders, especially 
neurological impairment. In sum, the research 
suggests that, in some circumstances, benzodiazepines 
can contribute to the risk of falls among elderly 
patients; the extent of this contribution alone is appar- 
ently not great, but merits consideration, together with 
other factors affecting the individual patient, in 
calculating the risks versus the benefits of  prescribing 
these drugs. 
While some earlier studies had demonstrated that 
benzodiazepines impair recall in elderly subjects, recent 
studies have appropriately sought to determine whether 
elderly subjects are in fact more sensitive to this effect 
than younger subjects. Testing of different age groups 
prior to drug administration, or under placebo condi- 
tions, demonstrates that recall abilities decline with age. 
Administration of benzodiazepines produces further 
decrements in recall in elderly subjects, but these are 
no greater proportionally than those produced in 
younger subjects (Hinrichs and Ghoneim 1987; Pomara 
et al. 1989; Greenblatt et al. I991). However, because 
of the baseline deficits in recall in the elderly, the addi- 
tional impairment produced by benzodiazepines may 
represent a more severe compromise. 
Triazolam 
Not long after triazolam was marketed, it was banned 
in the Netherlands in 1979 as a result of widely-publi- 
cized case reports of adverse behavioral effects. In 1991, 
the drug - which had become the most frequently pre- 
scribed hypnotic - was banned in the UK, and then 
banned or severely restricted in other Western 
European nations. The US Food and Drug 
Administration also reviewed the safety of triazolam 
in 1991, and concluded only that stricter limits for use 
should be recommended in labelling. These recent 
actions too were taken largely on the basis of case 
reports of untoward behavioral effects, which have by 
now appeared in record numbers. Regardless of their 
numbers, however, case reports cannot serve to estab- 
lish whether clinical phenomena can be attributed to 
drug use. Neither can they serve to estimate the inci- 
dence of possible drug reactions, since it is not clear 
how these may relate to the extent of use of the drug. 
in short, to address these questions meaningfully, case 
reports cannot substitute for controlled studies. 
Very few controlled studies have inquired into the 
incidence or nature of daytime distress during and after 
periods of nightly administration of triazolam. Some 
studies found certain adverse effects during and/or after 
treatment, including increased anxiety (Morgan and 
Oswald 1982; Kales et al. 1983) and apparent idiosyn- 
cratic reactions such as panic attacks, personality 
changes, and delusional episodes (Adam and Oswald 
1989); others have found no increased anxiety (Roth 
et al. 1976; Mamelak et al. 1984; Bliwise et al. 1988) 
or hostility (Roth et al. 1976) during triazolam treat- 
ment or upon discontinuation. Further controlled 
research is certainly needed to establish whether tria- 
zolam and/or other short-acting benzodiazepines can- 
produce such adverse effects, and if so what their nature 
and incidence might be. 
Restriction of benzodiazepine use 
Concerns about benzodiazepine use have led to vari- 
ous initiatives to restrict this use, both at the public 
health and clinical levels. In the last few years, some 
evidence has begun to emerge regarding the effects of  
such interventions. This information about the conse- 
quences of reducing or eliminating the availability of 
these drugs provides an important new perspective on 
the global significance of the use of benzodiazepines, 
and indeed of psychotherapeutic drugs in general. 
Government regulation 
From a scientific viewpoint, as described previously, it 
has been shown that it is inappropriate to regard ben- 
zodiazepines in the traditional context of  "drugs of 
abuse." Needless to say, however, this perspective 
lingers in some quarters, and continues to affect 
public policy decisions. The danger of this mispercep- 
tion is illustrated by a regulation imposed in New York 
State in 1989 because of the significant "public health 
danger posed by benzodiazepine abuse and misuse...." 
(Eadie 1990). The regulation stipulated, among other 
things, that benzodiazepine prescriptions can be issued 
only on the State's triplicate-copy prescription forms, 
of which one copy is forwarded to the State Department 
of Health for computerized monitoring. 
The effect of this regulation, in the year following 
its implementation, was that benzodiazepine prescrip- 
tions m the state declined by about half. At the same 
time, prescriptions substantially increased for a num- 
ber of nonbenzodiazepine drugs, which physicians 
apparently prescribed as substitutes for benzodi- 
azepines, e.g., meprobamate, barbiturates, and other 
sedative-hypnotics that are "older, less effective, and 
more hazardous" (Shader et al. 1991) than benzodi- 
azepines. However, the increase in prescriptions for sub- 
stitute drugs was not sufficient to offset the reduction 
in benzodiazepine prescriptions; thus another effect of  
the regulation may have been to exacerbate the long- 
standing problem of under treatment of anxiety and 
insomnia (Reidenberg 1991; Shader et al. 1991; 
Weintraub et al. 1991). 
In ten nursing homes in western New York 
State, 70% of patients who had been receiving 
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benzodiazepines were discontinued when the regula- 
tion went into effect. Most were switched to other 
psychoactive medications; for those who had been 
receiving benzodiazepine anxiolytics, the most frequent 
substitute was a neuroleptic, while the most frequent 
substitutes tbr benzodiazepine hypnotics were chloral 
hydrate and diphenhydramine (Zullich et al. 1992). 
In the 3 months after the regulation became effective, 
of the presentations at a New York City emergency 
room for problems associated with benzodiazepine use, 
half were clearly or probably related to the new regu- 
lation; most of these involved either frank withdrawal 
syndromes or re-emergence of anxiety disorders that 
had previously been controlled by benzodiazepine 
treatment (Schwartz and Blank 1991). In the year fol- 
lowing implementation of the regulation, benzodi- 
azepine overdoses in New York City significantly 
declined, whereas overdoses of other sedative-hypnot- 
ic drugs significantly increased; there was no overall 
change in the number of sedative-hypnotic overdoses 
(Hoffman et al. 1991). 
Clinical programs to discontinue long-term use 
Some psychiatric and other facilities have offered pro- 
grams for supervised discontinuation of long-term use 
of benzodiazepines. A number of recent studies have 
examined the outcomes of patients who participated in 
such programs. The great majority of patients who seek 
to end long-term use can achieve discontinuation 
(Rickels et al. 1986; Ashton 1987; Golombok et al. 
1987; Holton and Tyrer 1990), though some may 
require inpatient treatment to do so (Joughin et al. 
1991). Of those who successfully discontinue benzodi- 
azepine use, many patients experience clinical improve- 
ment in the short term (Cantopher et a1.1990; Rickels 
et al. 1990; Schweizer et al. 1990). There is some 
evidence that those who remain abstinent for long peri- 
ods continue to do well (Rickels et al. 1991; Schwartz 
and Blank 1991), but the corollary interpretation is that 
those who do not do welt resume treatment. Most stud- 
ies find that, w4thin about a year after discontinuing 
long-term benzodiazepine treatment, half to two thirds 
of patients have experienced relapse of their original 
symptoms (Higgitt et al. 1985; Rickels et al. 1986; 
Golombok et al. 1987); and about half of these patients 
have resumed benzodiazepine use (Higgitt et al. 1985; 
Rickels et al. 1986; Priebe et al. 1988; Cantopher et al. 
1990). Studies that have followed patients for longer 
periods after discontinuation, i.e. 3-6 years, find that 
the majority of patients have resumed benzodiazepine 
use for some period or are still taking them (Holton 
and Tyrer 1990; Rickels et al. i991). 
In addition to providing these rough estimates of the 
results of discontinuing long-term benzodiazepine use, 
these studies raise basic questions about the objectives 
of discontinuation. Should abstinence per se be the sole 
or primary criterion of "success?" In one study of dis- 
continuation of chronic benzodiazepine use, 14 of 21 
patients remained abstinent after 6 months. Based on 
ratings of clinical status, however, four of these patients 
had a "poor" outcome, of whom three had required 
psychiatric hospitalization; two other patients com- 
mitted suicide, at 4 and 14 months after discontinua- 
tion of benzodiazepine treatment (Joughin et al. 1991). 
Comment 
Since benzodiazepines act as CNS depressants, it was 
originally assumed that these drugs would share the 
high liability for abuse traditionally associated with 
sedative-hypnotics. Three decades of extensive experi- 
mental, clinical, and epidemiological experience have 
shown that this assumption was erroneous; benzodi- 
azepines have little liability for abuse in the general 
population or typical patient populations. 
Benzodiazepines can produce physiological depen- 
dence. This dependence does not appear to be associ- 
ated with psychological dependence or "addiction," 
which might be accompanied by inappropriate and pos- 
sibly harmful drug-seeking and -taking behaviors, such 
as escalation of doses. On the contrary, there is no per- 
suasive evidence of harm associated with physiological 
dependence on benzodiazepines, apart from the 
discomfort of withdrawal upon discontinuation. With- 
drawal may be more intense following discontinua- 
tionof the short-acting than of the longer-acting agents. 
In any case, withdrawal distress can be minimized by 
gradual tapering of dosage. 
A substantial number of patients who receive pre- 
scriptions for benzodiazepines continue to use these 
drugs for long periods. While we have an immense body 
of knowledge about many of the effects of benzodi- 
azepines, we have very little information about either 
the benefits or the risks of long-term use. The standard 
instruments for evaluation of the effects of anxiolytics 
and hypnotics in humans were designed to examine rel- 
atively short periods of treatment; new approaches may 
be required to examine effects of long-term use. 
Most people afflicted by anxiety or insomnia go 
without treatment (Consensus Conference 1984; 
Mellinger et al. 1984b). This represents a great deal of 
suffering, much of it probably unnecessary; and there 
is evidence linking untreated anxiety with increased 
risks of depression (Lesser et al. 1988), alcoholism 
(Regis et al. 1988), suicide (Fawcett 1988), and death 
due to unnatural causes (Coryell et al. 1982). 
Benzodiazepines currently represent the best treat- 
ments available for anxiety and insomnia. It is impor- 
tant to ensure the availability of these drugs for their 
intended therapeutic purposes. Initiatives that might 
restrict this availability should be undertaken only if 
they can be shown likely to produce benefits greater 
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than  their risks (Woods  1990). As  d e m o n s t r a t e d  by  the 
experience in N e w  York  State, increased restr ic t ion o f  
the overall  availability o f  benzod iazep ines  poses  seri- 
ous dangers  to the publ ic  heal th.  This regula t ion  led 
physic ians  to  prescr ibe less effective a nd  m o r e  haz-  
a r d o u s  drugs  for  some  patients,  a nd  to  leave others  
w i thou t  t r ea tment  o f  any  kind.  
Similarly, the decis ion to con t inue  o r  d i scont inue  
benzod iazep ine  t r ea tmen t  in chron ic  users shou ld  
weigh the possible risks o f  d i scon t inua t ion  agains t  the 
possible benefits. T he  available evidence indicates  that ,  
while some  chron ic  users m a y  n o  longer  need  medica -  
t ion  and  m a y  in fact  improve  after  d i scont inua t ion ,  o th-  
ers experience relapse o f  their  or iginal  d isorders  a n d  
can  benefit  f r o m  con t inued  benzod iazep ine  therapy. 
This benefit /r isk calcula t ion,  like the decision to pre-  
scribe these drugs  in the first place, m u s t  be m a d e  by 
the phys ic ian  on  the basis o f  the c i rcumstances  affect- 
ing the individual  patient .  
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